EODData

MEMBERSHIP REGISTER LOG IN

FRA, KY4: Kyowa Kirin Co. Ltd

02 Oct 2025
LAST:

13.70

CHANGE:
 0.20		OPEN:
13.60		HIGH:
13.70		ASK:
0.00		VOLUME:
183
CHG(%):
1.48		PREV:
13.50		LOW:
13.60		BID:
0.00		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
02 Oct 2513.6013.7013.6013.70183
01 Oct 2513.4013.5013.4013.500
30 Sep 2513.1013.1013.0013.100
29 Sep 2512.9013.2012.9013.20183
26 Sep 2513.2013.2013.2013.20183
25 Sep 2513.1013.2013.1013.20183
24 Sep 2513.0013.0013.0013.00183
23 Sep 2513.3013.5013.3013.30183
22 Sep 2513.3013.6013.3013.3050
19 Sep 2513.4013.4013.3013.40200

COMPANY PROFILE

Name:Kyowa Kirin Co. Ltd
About:Kyowa Kirin Co., Ltd. engages in the research, development, manufacturing, sells, and import/export of pharmaceuticals products worldwide. It's pipeline consist of OTL-203, which is in Phase III clinical trial for the treatment of hurler syndrome; KHK4083/AMG 45, which is in Phase III and II clinical trial for the treatment of atopic dermatitis and prurigo nodularis, and asthma; OTL-201, which is in Phase II clinical trial for the treatment of sanfilippo syndrome type A; ziftomenib, which is in Phase II and I clinical trial for the treatment of acute myeloid Leukemia and acute lymphoblastic leukemia; KHK4951, which is in Phase II clinical trial for the treatment of diabetic macular edema and neovascular age-related macular degeneration; KK8123, which is in Phase I clinical trial for the treatment of x-linked hypophosphatemia; KK2845, which is in Phase I clinical trial for the treatment of acute myeloid leukemia; KK4277, which is in Phase I clinical trial for the treatment of systemic and cutaneous lupus erythematosus; and KK2260 and KK2269 that are in Phase I clinical trial for the treatment of solid tumors. It also develops POTELIGEO, a humanized monoclonal antibody for CC chemokine receptor 4; REGPARA for secondary hyperparathyroidism; Romiplate/Nplate, a genetically recombinant protein that produces platelet; Crysvita, a recombinant human monoclonal IgG1 antibody; NESP, an erythropoiesis stimulating agent; GRAN, a human colony-stimulating factor; and LUMICEF, a biological treatment for moderate to severe plaque psoriasis. In addition, it offers G-Lasta; Duvroq; PHOZEVEL; KK8398; KHK4827; and OTL-200. It has an agreement with Amgen Inc. and Kura Oncology. The company was formerly known as Kyowa Hakko Kirin Co., Ltd. and changed its name to Kyowa Kirin Co., Ltd. in June 2019. The company was incorporated in 1949 and is headquartered in Tokyo, Japan. Kyowa Kirin Co., Ltd. is a subsidiary of Kirin Holdings Company, Limited.
Sector:Healthcare
Address:1-9-2, Otemachi, Tokyo, Japan, 100-0004
Website:https://www.kyowakirin.com
ISIN:JP3256000005
LEI:529900TBXKVTQGYA3582

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

P/E Ratio:34.88
DivYield:0.03
Div/Share:59.00
Price to Book:1.61
Price to Sales:0.02
EBITDA:95.64B
Shares:523.49M
Market Cap:7.172B

TECHNICAL INDICATORS

MA5:13.34
MA10:13.29
MA20:13.79
MA50:14.52
MA100:14.40
MA200:13.92
STO9:100.00
STO14:53.85
RSI14:36.36
WPR14:-46.15
MTM14:-0.60
ROC14:-0.04
ATR:0.23
Week High:13.70
Week Low:12.90
Month High:15.10
Month Low:12.90
Year High:16.25
Year Low:12.24
Volatility:7.73

RECENT DIVIDENDS

Date Amount
27 Jun 2025$0.17
27 Dec 2024$0.17
27 Jun 2024$0.17
28 Dec 2023$0.17
29 Jun 2023$0.16
29 Dec 2022$0.16
29 Jun 2022$0.14
29 Dec 2021$0.13
29 Jun 2021$0.13
30 Dec 2020$0.13